Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...

Discover why Gilead Sciences is a strong buy with potential blockbuster drugs in HIV and oncology, favorable valuation, and a ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $84.95 which represents a slight increase of $0.28 or 0.33% from the prior close of $84.67. The stock opened at $84 ...

The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North ...

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...

GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...

Why Gilead cut a deal with 6 generics companies around a yet-to-be-approved, twice-a-year HIV PrEP drug: "It really is all ...

Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell ...

US pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell ...

Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of ...

The stock's fall snapped a two-day winning streak.